mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-03 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
== Veterinary use == The veterinary use of chlorpromazine has generally been superseded by the use of acepromazine. Chlorpromazine may be used as an antiemetic in dogs and cats, or, less often, as a sedative before anesthesia. In horses, it often causes ataxia and lethargy and is therefore seldom used. It is commonly used to decrease nausea in animals that are too young for other common antiemetics. It is sometimes used as a preanesthetic and muscle relaxant in cattle, swine, sheep, and goats. The use of chlorpromazine in food-producing animals is not permitted in the European Union, as a maximum residue limit could not be determined following assessment by the European Medicines Agency.
18 August A weak spot in the spike protein of SARS-CoV-2 is described by researchers, which an antibody fragment called VH Ab6 can attach to, potentially neutralising all major variants of the virus. On 11 August, researchers report a single antibody, SP1-77, that could potentially neutralize all known variants of the virus via a novel mechanism, not by not preventing the virus from binding to ACE2 receptors but by blocking it from fusing with host cells' membranes. Multiple gene editing of soybean is shown to improve photosynthesis and boost yields by 20%. A researcher reports that the social media app TikTok adds a keylogger to its, on iOS essentially unavoidable, in-app browser in iOS, which allows its Chinese company to gather, for example, passwords, credit card details, and everything else that is typed into websites opened from taps on any external links within the app. Shortly after the report, the company claims such capabilities are only used for debugging-types of purposes. To date, it has largely not been investigated which and to which extent (other) apps have capacities for such or similar data-collection. A university reports the development of an invisible coating for fireproof wood. 20 August – A GBD systematic analysis reports the (non)progress on cancer and its causes during the 2010-19 decade, with ~44% of all cancer deaths in 2019 – or ~4.5 M deaths or ~105 million lost DALYs – due to known clearly preventable risk factors (contributions), led by smoking, alcohol use and high BMI.
== Effects on diabetes == Purinergic receptors have been implicated in the vascular complications associated with diabetes due to the effect of high-glucose concentration on ATP-mediated responses in human fibroblasts.
=== July === 1 July Ofgem lowers the energy price cap, saving the average household £122 a year on gas and electric. Passenger and crew of British Airways Flight 149, which was seized by Iraqi authorities when it landed at Kuwait International Airport in August 1990 at the start of the Gulf crisis, are to sue British Airways and the UK government for "deliberately endangering" them after they were held hostage by Iraq. For the second time in three months, military horses break free and run loose through central London. Euro 2024: UEFA investigate Jude Bellingham for a gesture he made following his late equaliser against Slovakia in England's victory in the last-16 tie. Bellingham says it was an inside joke directed at close friends. 2 July Three-time tennis champion Andy Murray, 37, withdraws from the Wimbledon singles, following recent surgery on his back. He will attempt to compete in the doubles, which are likely to mark his final appearance in the tournament prior to retiring later in the year. Following her conviction in August 2023, former neonatal nurse Lucy Letby is found guilty in a separate retrial of attempting to murder a premature child, referred to in court as Baby K. St James's University Hospital nursing assistant Mohammad Farooq is convicted at Sheffield Crown Court of crimes relating to plotting lone wolf attacks on RAF Menwith Hill in North Yorkshire and his Leeds workplace. Data obtained by BBC News shows that 1.8 million people owe at least £50,000 in student debt.
Sources: en.wikipedia.org
Obesity is a medical condition, considered a disease by multiple organizations, in which excess body fat has accumulated to such an extent that it can have negative effects on health. People are classified as obese when their body mass index (BMI)—a person's weight divided by the square of the person's height—is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight. Some East Asian countries use lower BMI thresholds to define obesity. Obesity is a major cause of disability and is correlated with various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, certain types of cancer, and osteoarthritis. Obesity has individual, socioeconomic, and environmental causes. Some known causes are diet, low physical activity, automation, urbanization, genetic susceptibility, medications, mental disorders, economic policies, and endocrine disorders. Exposure to endocrine-disrupting chemicals is a risk factor. While many people with obesity attempt to lose weight and are often successful, maintaining weight loss long-term is rare. Preventing obesity requires a multifaceted approach, including interventions at medical, societal, community, family, and individual levels. Changes to diet as well as exercising are the main treatments recommended by health professionals. Diet quality can be improved by reducing the consumption of energy-dense foods, such as those high in fat or sugars, and by increasing the intake of dietary fiber.
== Crotonyl-CoA and reductases == Before a 2007 report by Alber and coworkers, crotonyl-CoA carboxylases and reductases (CCRs) were known for reducing crotonyl-CoA to butyryl-CoA. A report by Alber and coworkers concluded that a specific CCR homolog was able to reduce crotonyl-CoA to (2S)-ethyl malonyl-CoA which was a favorable reaction. The specific CCR homolog came from the bacterium Rhodobacter sphaeroides. Crotonyl-CoA reductases belong to a broader class of enzymes that catalyze reduction reactions involving coenzyme A thioesters, often contributing to the biosynthesis of complex metabolites in microorganisms. These enzymes are particularly important in metabolic pathways that generate precursors for polyketide synthesis and other secondary metabolites.
The overall pulp cavity may become smaller by the addition of secondary or tertiary dentin and cause pulp recession. The lack of sensitivity associated with older teeth is due to receded pulp horns, pulp fibrosis, the addition of dentin, or all these changes. Restorative treatment can be performed without local anaesthesia on older dentitions.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.